Abstract
A substantial number of patients with advanced germ-cell tumors who relapse within 2 years of initial cisplatin-based chemotherapy can be rendered long-term survivors either with salvage chemotherapy (various cisplatin-based triplet regimens) or with high-dose chemotherapy — typically carboplatin plus etoposide with stem-cell rescue. Despite this demonstrated utility, the settings in which high-dose chemotherapy can be applied optimally remain unclear. In two earlier prospective trials of high-dose chemotherapy — one as initial therapy in patients with poor-risk disease (Journal Watch Hematology and Oncology Feb 5 2007) and one …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
